About
Alex Levental joined Ironwood Capital in 2005. He is an member of the Ironwood…
Activity
-
In the world of technology and sport, I’ve never met someone as connected as Stephen M. Brackett. His network? Unmatched. His impact? Revolutionary.…
In the world of technology and sport, I’ve never met someone as connected as Stephen M. Brackett. His network? Unmatched. His impact? Revolutionary.…
Liked by Alex Levental
Experience
-
-
-
-
-
-
-
-
-
Education
-
Colby College
-
Activities and Societies: Received George F. Baker Scholarship, Economics Department Research Assistant, Economics Department Student President, Co-author Colby Economic Outlook (CEO)
-
-
-
-
Languages
-
Russian
-
-
Ukrainian
-
-
English
-
Other similar profiles
Explore more posts
-
Michael Sidgmore
With news of HPS Investment Partners, LLC discussing a prospective IPO, which alternative asset managers are next in line to cross the chasm to public markets? In this week's Alt Goes Mainstream AGM Alts Weekly, I highlight some of the attributes that indicate that an alternative asset manager could be on the path to a public offering and share a list of some that could go public. Silver Lake Vista Equity Partners Clearlake Capital Group General Atlantic Warburg Pincus LLC Ardian Bain Capital HarbourVest Partners Hellman & Friedman Thoma Bravo Advent International Insight Partners Clayton Dubilier & Rice Who is next in line for an IPO? Read this week's AGM Weekly brought to you by Intapp (Intapp DealCloud ) for thoughts on how firms can go public: https://lnkd.in/eVrveeEt
-
Asher Abraham
An interesting conversation on Capital Allocators podcast with Brian Gaffney, CPA Partner at STONEHAVEN, LLC about the common challenges with background checks, and how Intelligo, an Israeli risk intelligence and background check platform that blends human analysis with cutting-edge AI to uncover facts in a fraction of the time - helps his team streamline their due diligence process. https://lnkd.in/djJHAaU7 #privatemarket #fintech #ai
1 Comment -
43North
TRACT10N: From Investment to IPO In 2021, we witnessed a moment that marked a milestone not just for 43North, but for Buffalo’s entire startup ecosystem. ACV Auctions, led by Joe Neiman, Dan Magnuszewski, Jack Greco, and George Chamoun, became a publicly traded company—our first IPO. As we celebrate 10 years of 43North, we look back on this incredible achievement with pride and excitement, hopeful that this is just the beginning of many more IPOs to come. #ThePowerof10 #ACVAuctions #BuffaloInnovation #IPO #Buffalo #Startup #43North10Years
-
How To SaaS
Question: What do finance, marketing, and sales have in common? Answer: They’re the three areas Craig Dupper, Founder and Managing Partner at Elan Growth Partners, consistently sees founder-led businesses underinvesting in. For actionable insights into how companies can address this challenge, plus lots more, tune in to this week’s episode of the Private Equity Value Creation podcast. Listen now 👇 https://lnkd.in/gTmh3xzR
-
Arthur Andrew Bavelas
Today LIVE in 1 hour: Lead investor Andreessen Horowitz (a16z) Bio + Health team in Arda Therapeutics joins us today for Family Office Insights Mercury Series Webinar featuring Adam Freund of Arda Therapeutics. Today: June 10 2024, 02:15 PM Eastern Time : RSVP: https://lnkd.in/gNyhUPuh Cells are the functional units of life. They are also the functional units of disease: many chronic diseases are caused by certain cell populations becoming too abundant or active. For example, subsets of stromal cells drives fibrosis, while the hyperactivity of particular immune cells leads to chronic inflammation. Arda Therapeutics is developing medicines to precisely remove these pathogenic cells, thereby treating diseases more effectively than by blocking individual proteins or signaling pathways. Their proprietary, single-cell-based discovery engine identifies pathogenic cells and specific markers to target them. They then design therapies to eliminate these - and only these - cells.
-
Fidelity Private Shares
What do VC's look for when evaluating founders to invest in? To answer this question, Fidelity Private Shares' Kristen Craft recently sat down with Lily Lyman, General Partner at Underscore VC, a Boston-based early-stage venture firm focused on pre-seed & seed-stage investments. Read on for her tips for raising capital: https://hubs.ly/Q02x_4s60 #venturecapital #founders #startups
2 Comments -
Capital Acceleration for Sovereign Technology And Resilience
J2 Ventures, a firm led mostly by U.S. military veterans, announced on Thursday that it has raised a $150 million second fund. The Boston-based firm invests in startups whose products are purchased by civilians and the U.S. Department of Defense. While many emerging VCs are struggling to raise second funds, J2’s latest vehicle is more than double its $67.5 million debut fund from 2021. At first blush, the firm may seem to be benefiting from VCs’ growing interest in defense tech. But J2 has no interest in positioning itself as a defense tech investor. “Our portfolio is national-security adjacent, but not defense-focused,” said Alexander Harstrick, J2’s managing partner. The firm does not invest in technologies that protect critical national infrastructure or help deter attacks, such as drones, robotics, or surveillance tech. Instead, J2 backs companies whose products help maintain the well-being and healthcare of nearly 3 million people employed by the U.S. military. https://buff.ly/3XRS7Bl
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More